Loading...
•
Apr 02, 2022
Bioventus Q1 2022 Earnings Report
Reported financial results for the first quarter of 2022 and reaffirmed full-year 2022 financial guidance
Key Takeaways
Bioventus reported a strong start to the year with a 43.4% increase in net sales compared to the previous year. The company's commercial organization performed well, and integration plans progressed. However, the company experienced a net loss of $14.8 million, compared to a net income of $24.5 million in the prior-year period, and a decrease in Adjusted EBITDA to $7.1 million from $11.1 million in the prior-year period.
Net sales reached $117.3 million, a 43.4% increase year-over-year as reported and 8.6% organically.
The company experienced a net loss of $14.8 million, compared to a net income of $24.5 million in the prior-year period.
Adjusted EBITDA was $7.1 million, compared to $11.1 million in the prior-year period.
The company reaffirmed its full-year 2022 financial guidance.
Bioventus
Bioventus
Bioventus Revenue by Geographic Location
Revenue by Geographic Location
U.S. Revenue
CapyFin.comInternational Revenue
CapyFin.com Forward Guidance
For the twelve months ending December 31, 2022, the Company expects net sales of $545 million to $565 million, representing year over year growth of approximately 26% to 31%, and Adjusted EBITDA of $94 million to $107 million, compared to $80.8 million for the year ended December 31, 2021.
Positive Outlook
- Net sales of $545 million to $565 million, representing year over year growth of approximately 26% to 31%.
- Adjusted EBITDA of $94 million to $107 million, compared to $80.8 million for the year ended December 31, 2021.
Challenges Ahead
- The Company does not provide U.S. GAAP financial measures, other than net sales, on a forward-looking basis because the Company is unable to predict with reasonable certainty the impact and timing of acquisition related expenses, accounting fair-value adjustments, and other reconciling items without unreasonable efforts.
- The Company is not providing guidance for adjusted diluted earnings per share due to the uncertainty of the timing for its potential CartiHeal acquisition, but will provide guidance after completion of any acquisition.
- The Company's guidance reflects its current expectations regarding the impact of COVID-19 on its business.
- The severity and duration of the COVID-19 pandemic are outside of the Company’s control and, given the uncertain nature of the pandemic, could cause the Company’s future operating results to be different from our current expectations, particularly if the impact of the pandemic worsens.
Revenue & Expenses
Visualization of income flow from segment revenue to net income